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Summary The aim of the study was to determine the maximum tolerated dose (MTD) for the combination of
high-dose epirubicin and vinorelbine in chemotherapy-naive patients with inoperable non-small-cell lung
cancer (NSCLC). Twenty-one patients with stage IIIB and IV NSCLC were treated in a single-centre study
with escalating doses of epirubicin and vinorelbine given on an outpatient basis. The first dose level comprised
epirubicin 100 mg m-2 on day I and vinorelbine 20 mg m-2 (days 1 and 8) given intravenously every 3 weeks.
Escalating doses for epirubicin and vinorelbine were respectively 120 (day 1) and 20 (days I and 8), 120 (day
1) and 25 (days 1 and 8) and 135 (day 1) and 25 (days 1 and 8) mg m2. Inclusion criteria were age <75
years, ECOG performance score <2 and normal renal, hepatic and bone marrow functions. Dose-limiting
toxicities were thrombocytopenia grade II and neutropenia grade III on day 8, febrile neutropenia, and
neutropenia lasting >7 days. No dose-limiting toxicity (DLT) was observed at the first dose level; at the
135/25 mg m-2 dose level three out of six patients had a DLT which was considered as unacceptable. The only
non-haematological toxicity reaching grade III was nausea/vomiting. One patient showed cardiac toxicity. No
neurotoxicity and no treatment-related deaths were seen. The maximum tolerated dose of epirubicin and
vinorelbine is 135 mg m-2 (day 1) and 25 mg m-2 (days 1 and 8) respectively, causing mainly haematological
toxicity. The recommended dose of epirubicin and vinorelbine for phase II studies is found to be 120 mg m2
and 20mg m2 respectively.
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Patients with non-small-cell lung cancer (NSCLC) are often
diagnosed with locally advanced or disseminated disease des-
pite few or no symptoms. Median survival for patients with
advanced locoregional inoperable NSCLC is 8-10 months
(Bunn, 1991), for patients with metastatic NSCLC median
survival is 6 months (Ihde, 1992). To improve the prognosis
of patients with inoperable NSCLC, chemotherapy with or
without radiotherapy is the only currently available treatment
modality. A meta-analysis of results of (combination)
chemotherapy trials in these patients has shown improvement
of survival compared with best supportive care only (Souquet
et al., 1993), although the benefit at 1 year is only marginal
(Grilli et al., 1993). A limited number of cytotoxic drugs
induce more than 15% objective responses as single agent in
NSCLC. One of these agents is epirubicin, the 4' epimer of
the anthracycline antibiotic doxorubicin (DXR). The major
acute dose-limiting toxicity (DLT) of anthracyclines is
myelosuppression; the most important chronic DLT is car-
diotoxicity which is manifested as irreversible car-
diomyopathy (Plosker et al., 1993). In previous comparative
studies vs DXR, epirubicin has demonstrated less bone mar-
row and cardiac toxicity at equipotent dosages; its major
acute DLT is myelosuppression (Launchbury and Habboubi,
1993). In NSCLC high-dose epirubicin (> 120 mg m-2) as a
single agent has shown promising objective response rates of
21-56% (Wils et al., 1990; Martoni et al., 1991; Villar et al.,
1991; Feld et al., 1992; Smit et al., 1992). One way to
improve these results is to combine high-dose epirubicin with
other active agents in NSCLC. Vinorelbine (nor-5'anhydro-
vinblastine) is a new semisynthetic vinca alkaloid chemically
different from vinblastine by a substitution of the catharan-
thine moiety. Like other vinca alkaloids, vinorelbine inhibits
tubulin polymerisation into microtubules, and as in the
parent vinblastine, neurotoxicity appears to be mild (Kri-
korian et al., 1991; Zhou et al., 1992). Vinorelbine has been
under investigation in phase II trials and showed activity
against NSCLC with response rates ranging from 14% to
65% (Cvitovic et al., 1992; Sorensen, 1992; Lilenbaum et al.,
1993). The major toxicities of vinorelbine are myelosuppres-
sion and nausea and vomiting. One large multicentre study
has shown favourable survival rates for vinorelbine combined
with cisplatin compared with single-agent vinorelbine (Le
Chevalier et al., 1994). We conducted a phase I study com-




Between March 1992 and January 1994 21 patients were
entered into this study. Eligibility criteria were histologically
proven NSCLC with disseminated or unresectable disease not
amenable to surgery. No prior chemotherapy was allowed.
Patients who had received prior radiotherapy had to have
finished treatment at least 4 weeks before entry. Additional
inclusion criterion were age between 18 and 75 years, Eastern
Cooperation Oncology Group (ECOG) performance score
(PS)<2, white blood count (WBC) >4.0 x 1091-1, neut-
rophils>2.0 x 1091-, platelets >100 x 1091-, bilirubin<
35 tmoll-[ and creatinine<120tgmoll1'. Patients wtih
symptomatic brain metastases, myocardial infarction within
the last 12 months, left ventricular ejection fraction (LVEF)
less than 90% oflower normal institutional limit as measured
by multiple ECG-gated radionuclide study (MUGA scan),
arrhythmias requiring permanent medication, uncontrolled
hypertension or ischaemic heart disease were ineligible.
Approval of the Medical Ethical Committee of the Univer-
sity Hospital in Groningen, The Netherlands, was obtained,
and all patients gave written informed consent before entry
into the study. Before treatment all patients underwent
baseline measurements of bone marrow and cardiac function
and staging procedures including physical examination, chest
radiograph, computerised tomography (CT) scan of thorax
and upper abdomen, ECG and MUGA scan and laboratory
tests including complete blood cell counts, electrolytes, liver
and renal functions. Additional studies including bone scin-
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tigraphy or CT scan of the brain were performed on indica-
tion of suspected metastases.
Toxicity
Toxicity was measured according to the WHO grading
system (WHO, 1978). Complete blood cell counts including
WBC and differentials were performed on days 1, 8, 10, 12,
15, 17 and 22 of each course. In the last week of each course
an ECG was obtained, and liver and renal functions as well
as tumour measurements and toxicity scores were deter-
mined. LVEF was measured by MUGA scan after three
cycles and/or at discontinuation of therapy. Patients who
completed treatment were assessed for chronic toxicity every
2 months until death. Haematological DLT was defined as
WHO grade III neutropenia or thrombocytopenia grade II
on day 8, grade IV neutropenia lasting longer than 7 days,
febrile neutropenia or thrombocytopenia grade IV at any
time during the cycle. Non-haematological DLT was defined
as any toxicity exceeding WHO grade II (except alopecia)
and nausea and vomiting exceeding WHO grade III. Cardiac
toxicity was defined as symptomatic cardiac failure and/or a
decrease in LVEF of more than 15% from baseline or more
than 10% below the lower normal institutional limit (55%).
Dose and dose adjustments
Epirubicin was dissolved in 250 ml 0.9% sodium chloride
and given on day 1 as a 30 min intravenous (i.v.) infusion.
Vinorelbine was dissolved in 125 ml 0.9% sodium chloride
and given on days 1 and 8 as a 10 min i.v. infusion. The
interval between courses was 3 weeks with a maximum of six
cycles or until disease progression. The starting dose of
epirubicin (E) was 100 mg m-2 on day 1, and that of vinorel-
bine (V) 20 mg m-2 on days 1 and 8. Level II consisted of E
120 (day 1) and V 20 mg m-2 (days 1 and 8), level III: E 120
(day 1)/V (days 1 and 8) 25 mg m-2 and level IV: E 135 (day
1)/V 25 mgm2 (days 1 and 8) respectively. Routine pro-
phylaxis for nausea and vomiting (ondansetron chloride
2 x 8 mg oral on day 1 and 1 x 8 mg oral on day 2, dex-
amethasone 1 x 8 mg i.v. on day 1) was given at all dose
levels. At each level at least three patients were entered. If no
DLT was found during their first cycle, the following three
patients would start at the next dose level. Three additional
patients had to be treated at the same dose level if a single
patient experienced DLT in the first cycle. If not more than
two out of six patients reached DLT, patients were entered
into the next dose level. If at least three out of six patients
had one (or more) DLT at a certain dose level during the
first chemotherapy cycle, the study was finished. This level
was defined as the maximum tolerated dose (MTD); the dose
one level lower would be the recommended dose for phase II
studies. Dose adjustments or treatment delay up to a max-
imum of 14 days were made for neutrophil and platelet nadir
and day 21 counts. Criteria for dose modifications for
haematological toxicity are summarised in Table I. The dose
of both drugs had to be reduced by 50% if bilirubin was
between 35 and 50jLmo 1-' and/or aspartate aminotrans-
ferase (ASAT) was between three and five times upper nor-
mal limits in the absence of liver metastases. If bilirubin
levels were more than 50 ymol 1I- or ASAT more than five
times upper normal limits in the absence of liver metastases,
patients would go off study. In case of mucositis grade III or
IV the dose of both vinorelbine and epirubicin had to be
reduced by 25%.
Response criteria
Complete response (CR) indicated the disappearance of all
known disease, determined by two observations not less than
4 weeks apart. A partial response (PR) was defined as a
decrease by 50% or more in the sum of the products of the
two largest perpendicular diameters of all measurable lesions,
as determined by two consecutive observations not less than
4 weeks apart. A situation in which less than 50% decrease
or less than 25% increase in total tumour size occurred was
defined as stable disease or no change (NC). Progressive
disease (PD) was defined as >25% increase in the size of
one or more measurable lesions, or the appearance of new
lesions.
Results
Twenty-one patients were entered into this study: three
patients in dose level I and six patients each in dose levels II,
III and IV. Their characteristics are summarised in Table II.
No DLT was observed in the first dose level. At the second
dose level one patient had grade IV neutropenia. The same
patient showed WHO grade IV alanine aminotransferase
(ALAT) elevation in absence of known liver metastases.
Liver function tests returned to normal on day 22. At the
third dose level one patient had febrile neutropenia and grade
III neutropenia on day 8, another had grade IV neutropenia
lasting 8 days. At the fourth dose level, three patients
experienced a DLT (grade III neutropenia on day 8 in two
patients, and one patient with febrile neutropenia). At this
dose level, defined as the MTD, the study was closed. The
incidence (median duration, range) of WHO grade IV neut-
ropenia in the first cycle was 33% (one patient, duration 3
days) in level I, 100% in level II (3 days, 1-4 days) and IV (5
days, 1-6 days) and 84% in level III (3 days, 1-6 days). The
combination of epirubicin and vinorelbine induces short-lived
neutropenia. Myelosuppression was dose related. The median
nadirs of leucocytes, neutrophils and platelets are listed in
Table III. The median time to nadir counts was 12 days
(range 8-15 days). The percentages of cycles associated with
haematological toxicity >WHO grade III are shown in
Table IV. WHO grade IV leucopenia and neutropenia occur-
red in 14% and 50% of all cycles respectively. Four patients
Table I Criteria for dose modifications for haematological toxicity
Day 21 counts Nadir Dose adjustment
Neutrophils> 1.5 x IO' 1' Neutrophils >0.2 x IO' 1 100% of day 1 of previous cycle
AND AND (epirubicin and vinorelbine)
Platelets > I100 x 109 1-' Platelets>,50 x 109 1-'
Neutrophils ) 1.5 x 1091 Neutrophils<0.2 x 1091-' Reduce epirubicin and vinorelbine
AND OR to 75% of day 1 ofprevious cycle
Platelets>, I100 x 109 1- Platelets< 50 x 109 1-'
OR
Febrile neutropenia
Neutrophils < 1.5 x 1091' Any Hold therapy. Repeat CBC weekly
OR until neutrophils L.5 x 1091- AND
Platelets<100 x 109 1-' platelets>100 x 109 1- and then
treat patients with dose adjustments
according to nadir evaluation. If no
recovery is reached after 2 weeks the
patient will go off study
154
a RTable II Patient characteristics
Number of patients 21
Sex M/F 17/4


















Reason for discontinuation of treatment
PD 12
PD and decrease of LVEF 1
Patient refusal 2
Toxic deaths 0
aAccording to the American Joint Committee for Cancer Staging
(1986).
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had to be hospitalised for neutropenic fever for a total of six
admissions. Grade IV thrombocytopenia or anaemia was not
observed. Dose adjustments were necessary after the first (11
out of 13 dose reductions) and third course (two out of 13
dose reductions respectively) at all dose levels owing to a
neutrophil nadir<0.2 x 109 IP- in 11 and neutropenic fever
in two courses. At the fourth level one patient received more
than one full-dose course, the remaining five patients treated
at this dose level had dose reduction. None of the patients
required a second dose reduction. Only one course had to be
postponed for 1 week owing to insufficient haematological
recovery on day 21. Received dose intensity (RDI) in the
four levels in mg m-2 week-' was E/V 32/6.4 in level I, 37/6.2
in level II, 35/7.2 in level III and E/V 38/7.1 in level IV.
RDI/projected dose intensity (PDI) for the ascending dose
levels were 0.97, 0.93, 0.87 and 0.85 respectively. Non-
haematological toxicity consisted mainly of nausea/vomiting,
stomatitis and phlebitis. The percentages of cycles associated
with non-haematological toxicity are listed in Table V.
Twenty-eight cycles were associated with nausea/vomiting
grade I-III despite prophylactic anti-emetic treatment. The
median duration of nausea/vomiting was 2.5 days with a
range of 1-8 days. From their second or third cycle on, 16
out of 21 patients showed grade I or II phlebitis. Only two of
these patients had to be treated with analgesics. Neurotox-
icity was not observed. Cardiac toxicity could not be exc-
luded in one patient who complained of fatigue and slight
shortness of breath. LVEF measured by MUGA scan
decreased from 74% to 50% after four courses corresponding
to a total dose of 416 mg m-2 epirubicin. This patient even-
tually died of progressive disease measured on chest radio-
Table III Median (range) nadir of blood cell counts
Dose No. ofpatientsl WBC Neutrophils Platelets Haemoglobin
mgm-2 No. ofcycles 109l-] 109l-] 109l-] g lOOml-,
100/20 3/8 2.0 (1.2-3.1) 0.8 (0.2-1.3) 209 (140-386) 105 (88-113)
120/20 6/30 1.3 (0.7-2.3) 0.2 (0.1-0.6) 122 (36-199) 82 (68-113)
120/25 6/23 1.1 (0.4-2.5) 0.2 (0.01-0.5) 128 (87-192) 89 (76-127)
135/25 6/23 0.9 (0.2-2.0) 0.06 (0.02-0.2) 89 (76-118) 104 (56-274)
Table IV Cycles (%) with haematological toxicity>WHO III
Dose No. ofpatientsl Toxicity WBC Neutrophils Haemoglobin Platelets
(mgm-2) no. ofcycles grade (%) (%) (%) (%)
100/20 3/8 III 50 25 0 0
IV 0 40 0 0
120/20 6/30 III 27 7 0 3
IV 0 30 0 0
120/25 6/23 III 52 35 0 0
IV 17 48 0 0
135/25 6/23 III 22 9 4 0
IV 35 57 0 0
Table V Cycles (%) with non haematological toxicity
Nausea/
Dose No. ofpatients/ Toxicity vomiting Phlebitis Stomatitis
(mgm-2) No. ofcycles grade (%) (%) (%)
100/20 3/8 I 38 13 24
II 0 25 0
III 13 0 0
IV 0 0 0
120/20 6/30 I 13 23 7
II 13 7 3
III 3 0 0
IV 0 0 0
120/25 6/23 I 9 35 0
II 0 13 9
III 13 0 0
IV 0 0 0
135/25 6/23 I 30 22 4
II 13 4 0
III 0 0 0
IV 0 0 0High-dose epirubicin and vinorelbine in NSCLC
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graph, however, without clinical signs of congestive heart
failure. Sixteen patients had to be hospitalised during their
treatment for a total of 24 admissions. Reasons for hospital
admission were red blood cell transfusion (12 patients), neut-
ropenic fever (four patients), pneumonia (one patient) and
ischaemic colitis (one patient). Although tumour response
was not an end point of this study, we observed two partial
responses (one in level II and one in level III), and ten
patients with stable disease out of 20 evaluable patients.
Response durations were 12 and 4 weeks. Survival of this
group showed a range of 3-106 weeks with a median of 21
weeks (with one patient still alive at time of evaluation).
Discussion
The objective of this study was to determine the MTD of the
combination of high-dose epirubicin and vinorelbine in
chemotherapy-naive patients with grade IIIB-IV NSCLC.
We found neutropenia, neutropenic fever and throm-
bocytopenia on day 8 as dose-limiting toxicities. In this phase
I study we determined the MTD at 135 mgm2 epirubicin
(day 1) combined with 25 mg m-2 vinorelbine (days 1 and 8).
Leucocyte, neutrophil and platelet nadirs occurred on day 12
with dose-related myelosuppression. In only one out of 84
cycles haematological recovery was not complete before day
22. Non-haematological toxicity consisted mainly of nausea
and vomiting (in spite ofprophylactic anti-emetic treatment),
although neither this nor a frequently observed phlebitis of
the infusion vein has been a major problem. Cardiac toxicity
was possibly encountered in only one out of 21 patients; the
decrease in LVEF was not accompanied by clinical signs.
Analysis of other high-dose epirubicin studies has shown that
high incidences of decreasing LVEF go together with low
incidences of congestive heart failure (Feld et al., 1992).
Nielsen et al. (1990) conclude from their study of 135
epirubicin-treated patients that LVEF is of no predictive
value for congestive heart failure, and should only be
measured if there is clinical suspicion of cardiac disease. For
higher cumulative dosages endomyocardial biopsy may be
more indicative for congestive heart failure than LVEF (Torti
et al., 1986). A considerable risk of cardiac toxicity was
found in patients treated with a cumulative dose ofepirubicin
above 1000 mg m2 (Shepherd et al., 1989). Therefore, it is
questionable whether MUGA scans should be performed
routinely in patients who are treated at lower cumulative
dosages. In the present study no neurotoxicity and no
treatment-related deaths were observed. The MTD for
epirubicin and vinorelbine as established in this phase I study
differs from an earlier report (Gridelli et al., 1993). They
found an MTD of 60 mg m-2 epirubicin without granulocyte
colony-stimulating factor (G-CSF) and an MTD of 90 mg
m-2 epirubicin with G-CSF with a fixed dose of 25 mg m-2
vinorelbine. Myelosuppression was the dose-limiting toxicity
for both treatment groups, as it was in our study. Gridelli et
al. (1993) defined MTD as the dose that caused myelotoxicity
grade III in 50% of cases and grade IV in 20% of cases. In
our definition of MTD the duration of the neutropenia was
more important than the degree of nadir, which might ex-
plain the difference in MTD between these two studies.
Myelotoxicity in our study was comparable with that
reported for single-agent epirubicin at dosages of 160-180
mg m-2 (Feld et al., 1992). From data of this phase I study,
we conclude that combination treatment of high-dose
epirubicin with vinorelbine causes considerable toxicity. In
dose level III only two out of six patients could receive a
full-dose second course compared with four out of six
patients at dose level II. Also, the RDI in these two levels
were almost identical owing to more dose reductions in the
higher dose level. Both arguments suggest that dose level II
(epirubicin 120 mgm-2 combined with vinorelbine 20 mg
m-2) is the recommended dose for phase II studies. However,
as leuco- and neutropenia are the major toxicities of this
regimen, a more obvious combination might be high-dose
epirubicin with gemcitabine or carboplatin since these drugs
cause less leuco- and neutropenia compared with vinorelbine.
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